Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection

Shanghai Junshi Biosciences Co., Ltd. announced that the supplemental application for additional indications of adalimumab injection for the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children had been approved by the National Medical Products Administration.